- Email: [email protected]
Krauss-Maffei finds new home in the USA
issue.qxd
03/04/2003
12:01
Page 16
Filtration Industry Analyst
NEWS
KRAUSS-MAFFEI FINDS NEW HOME IN THE USA Krauss-Maffei Process Technology is investing US$2 million in a new facility in Kentucky for its US subsidiary, Krauss-Maffei Process Technology Inc USA. The new site will provide the necessary space for expansion. When finished, the main building will provide 15 000 ft2 (about 1400 m2) of space for centrifuge and dryer assembly, a repair shop and spare parts stock, served by cranes with up to 20-ton capacity. There will also be a separate 3000 ft2 laboratory for wet and dry product testing of pilot machines and factory acceptance tests of production machines and controls. Engineering, marketing and administrative staff will occupy an 8000 ft2 office building. Construction of the facility started in early November 2002 and its official opening is set for May this year. The six-acre site is just half a mile away from the company’s current location in 18 000 ft2 of space at former parent organization KraussMaffei Corp. The move follows the management buyout of Krauss-Maffei Process Technology in 2001 and its consequent legal separation from Krauss-Maffei Corp.
GEA FILTRATION ACQUIRES LIQUID TECHNOLOGIES GEA Filtration has acquired Liquid Technologies’ operations in New Zealand and Australia. Liquid Technologies has extensive experience in supplying membrane filtration plants and integrating them in complete process lines for the dairy industry. It will now expand its role in supplying membrane filtration solutions to the food & beverage,
16
March 2003
biotech & pharmaceutical, and process wastewater markets. The local sales network will be expanded with dedicated GEA Filtration personnel. In New Zealand, Liquid Technologies will now operate as a division of Niro NZ Ltd, and in Australia as a division of Niro Australia Pty Ltd. It will continue to represent GEA Filtration in both countries.
DOMNICK HUNTER PASSES NBC TRIALS Domnick Hunter Group plc’s nuclear, biological and chemical (NBC) protection technology has successfully completed UK and US Government evaluation programmes. According to the company, its NBC system is the world’s first in situ regenerative air filtration system. A prototype of the system has been tested in the UK using volatile simulants of typical chemical warfare agents. The tests were witnessed by officials from the Ministry of Defence as part of a £3.6 million order to supply Alvis Vickers Ltd for its Engineered Tank System. The air-purification technology has also passed full-scale interim trials by the Soldier, Biological, Chemical Command (SBCCOM), a division of the US Army. According to the company, existing NBC collective protection systems utilize ‘single pass’ carbon filters. Once used, the filters must be replaced – logistically difficult while vehicles are in operation in the field. In contrast, Domnick Hunter’s system contains a regenerative filtration unit, which cycles as necessary between two filter chambers; while one chamber is on-line the other is undergoing regeneration. The system can thus provide continuous purification, removing potentially contaminating nuclear, biological or chemical agents to
supply breathable air to personnel at risk inside armoured vehicles or in buildings or ships that may be subject to attack.
SHAW TO ACQUIRE ENVIROGEN Environmental protection company Envirogen Inc has entered into a merger agreement under which it will become a wholly-owned subsidiary of Shaw Environmental & Infrastructure Inc. “As part of Shaw Environmental, Envirogen will be better able to serve its existing customers and have access to a far greater number of potential customers,” said Envirogen president and CEO Robert Hillas. Shaw Environmental provides consulting, engineering, construction, remediation and facilities management services to the environmental, infrastructure and homeland defence markets. Under the terms of the agreement, Shaw Environmental will acquire all of Envirogen’s outstanding common stock for US$0.90 per share, or around US$3.6 million. Envirogen’s board of directors has unanimously approved the transaction and recommended that its stockholders vote in favour of the merger. Certain directors, executive officers and other stockholders of Envirogen, who collectively own more than 33% of Envirogen’s outstanding shares, have agreed to vote in favour of the proposed transaction. In other news, Envirogen has been delisted from the Nasdaq SmallCap Market. Hillas said that, in view of the pending merger, it would be unnecessarily costly to appeal against Nasdaq’s decision, with no ultimate benefit to shareholders. Envirogen’s common stock will now be traded on the OTC Bulletin Board.
Editorial Office Elsevier Advanced Technology PO Box 150 Kidlington Oxford OX5 1AS United Kingdom Tel: +44 (0)1865 843676 Fax: +44 (0)1865 843971 E-mail: [email protected] Web: www.filtsep.com Editor Helen Long Permissions may be sought directly from Elsevier Science Rights & Permissions Department, PO Box 800, Oxford OX5 1DX, UK; phone: (+44) 1865 843830, fax: (+44) 1865 853333, e-mail: permissions @elsevier.co.uk. You may also contact Rights & Permissions directly through Elsevier’s home page (http://www.elsevier.nl), selecting first ‘Customer Support’, then ‘General Information’, then Permissions Query Form’. In the USA, users may clear permissions and make payments through the Copyright Clearance Center, Inc., 222 Rosewood Drive, Danvers, MA 01923, USA; phone: (978) 7508400, fax: (978) 7504744, and in the UK through the Copyright Licensing Agency Rapid Clearance Service (CLARCS), 90 Tottenham Court Road, London W1P 0LP, UK; phone: (+44) (0)20 7436 5931 ; fax: (+44) (0)20 7631 5500. Other countries may have a local reprographic rights agency for payments. Derivative Works Subscribers may reproduce tables of contents or prepare lists of articles including abstracts for internal circulation within their institutions. Permission of the publisher is required for resale or distribution outside the institution. Permission of the publisher is required for all other derivative works, including compilations and translations. Electronic Storage or Usage Permission of the publisher is required to store or use electronically any material contained in this journal, including any article or part of an article. Contact the publisher at the address indicated. Except as outlined above, no part of this publication may be reproduced, stored in a retrieval system or transmitted in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, without prior written permission of the publisher. Address permissions requests to: Elsevier Science Rights & Permissions Department, at the mail, fax and e-mail addresses noted above. Notice No responsibility is assumed by the Publisher for any injury and/or damage to persons or property as a matter of products liability, negligence or otherwise, or from any use or operation of any methods, products, instructions or ideas contained in the material herein. Because of rapid advances in the medical sciences, in particular, independent verification of diagnoses and drug dosages should be made. Although all advertising material is expected to conform to ethical (medical) standards, inclusion in this publication does not constitute a guarantee or endorsement of the quality or value of such product or of the claims made of it by its manufacturer.
02207 Printed by Mayfield Press, Oxon, UK.
03/04/2003
12:01
Page 16
Filtration Industry Analyst
NEWS
KRAUSS-MAFFEI FINDS NEW HOME IN THE USA Krauss-Maffei Process Technology is investing US$2 million in a new facility in Kentucky for its US subsidiary, Krauss-Maffei Process Technology Inc USA. The new site will provide the necessary space for expansion. When finished, the main building will provide 15 000 ft2 (about 1400 m2) of space for centrifuge and dryer assembly, a repair shop and spare parts stock, served by cranes with up to 20-ton capacity. There will also be a separate 3000 ft2 laboratory for wet and dry product testing of pilot machines and factory acceptance tests of production machines and controls. Engineering, marketing and administrative staff will occupy an 8000 ft2 office building. Construction of the facility started in early November 2002 and its official opening is set for May this year. The six-acre site is just half a mile away from the company’s current location in 18 000 ft2 of space at former parent organization KraussMaffei Corp. The move follows the management buyout of Krauss-Maffei Process Technology in 2001 and its consequent legal separation from Krauss-Maffei Corp.
GEA FILTRATION ACQUIRES LIQUID TECHNOLOGIES GEA Filtration has acquired Liquid Technologies’ operations in New Zealand and Australia. Liquid Technologies has extensive experience in supplying membrane filtration plants and integrating them in complete process lines for the dairy industry. It will now expand its role in supplying membrane filtration solutions to the food & beverage,
16
March 2003
biotech & pharmaceutical, and process wastewater markets. The local sales network will be expanded with dedicated GEA Filtration personnel. In New Zealand, Liquid Technologies will now operate as a division of Niro NZ Ltd, and in Australia as a division of Niro Australia Pty Ltd. It will continue to represent GEA Filtration in both countries.
DOMNICK HUNTER PASSES NBC TRIALS Domnick Hunter Group plc’s nuclear, biological and chemical (NBC) protection technology has successfully completed UK and US Government evaluation programmes. According to the company, its NBC system is the world’s first in situ regenerative air filtration system. A prototype of the system has been tested in the UK using volatile simulants of typical chemical warfare agents. The tests were witnessed by officials from the Ministry of Defence as part of a £3.6 million order to supply Alvis Vickers Ltd for its Engineered Tank System. The air-purification technology has also passed full-scale interim trials by the Soldier, Biological, Chemical Command (SBCCOM), a division of the US Army. According to the company, existing NBC collective protection systems utilize ‘single pass’ carbon filters. Once used, the filters must be replaced – logistically difficult while vehicles are in operation in the field. In contrast, Domnick Hunter’s system contains a regenerative filtration unit, which cycles as necessary between two filter chambers; while one chamber is on-line the other is undergoing regeneration. The system can thus provide continuous purification, removing potentially contaminating nuclear, biological or chemical agents to
supply breathable air to personnel at risk inside armoured vehicles or in buildings or ships that may be subject to attack.
SHAW TO ACQUIRE ENVIROGEN Environmental protection company Envirogen Inc has entered into a merger agreement under which it will become a wholly-owned subsidiary of Shaw Environmental & Infrastructure Inc. “As part of Shaw Environmental, Envirogen will be better able to serve its existing customers and have access to a far greater number of potential customers,” said Envirogen president and CEO Robert Hillas. Shaw Environmental provides consulting, engineering, construction, remediation and facilities management services to the environmental, infrastructure and homeland defence markets. Under the terms of the agreement, Shaw Environmental will acquire all of Envirogen’s outstanding common stock for US$0.90 per share, or around US$3.6 million. Envirogen’s board of directors has unanimously approved the transaction and recommended that its stockholders vote in favour of the merger. Certain directors, executive officers and other stockholders of Envirogen, who collectively own more than 33% of Envirogen’s outstanding shares, have agreed to vote in favour of the proposed transaction. In other news, Envirogen has been delisted from the Nasdaq SmallCap Market. Hillas said that, in view of the pending merger, it would be unnecessarily costly to appeal against Nasdaq’s decision, with no ultimate benefit to shareholders. Envirogen’s common stock will now be traded on the OTC Bulletin Board.
Editorial Office Elsevier Advanced Technology PO Box 150 Kidlington Oxford OX5 1AS United Kingdom Tel: +44 (0)1865 843676 Fax: +44 (0)1865 843971 E-mail: [email protected] Web: www.filtsep.com Editor Helen Long Permissions may be sought directly from Elsevier Science Rights & Permissions Department, PO Box 800, Oxford OX5 1DX, UK; phone: (+44) 1865 843830, fax: (+44) 1865 853333, e-mail: permissions @elsevier.co.uk. You may also contact Rights & Permissions directly through Elsevier’s home page (http://www.elsevier.nl), selecting first ‘Customer Support’, then ‘General Information’, then Permissions Query Form’. In the USA, users may clear permissions and make payments through the Copyright Clearance Center, Inc., 222 Rosewood Drive, Danvers, MA 01923, USA; phone: (978) 7508400, fax: (978) 7504744, and in the UK through the Copyright Licensing Agency Rapid Clearance Service (CLARCS), 90 Tottenham Court Road, London W1P 0LP, UK; phone: (+44) (0)20 7436 5931 ; fax: (+44) (0)20 7631 5500. Other countries may have a local reprographic rights agency for payments. Derivative Works Subscribers may reproduce tables of contents or prepare lists of articles including abstracts for internal circulation within their institutions. Permission of the publisher is required for resale or distribution outside the institution. Permission of the publisher is required for all other derivative works, including compilations and translations. Electronic Storage or Usage Permission of the publisher is required to store or use electronically any material contained in this journal, including any article or part of an article. Contact the publisher at the address indicated. Except as outlined above, no part of this publication may be reproduced, stored in a retrieval system or transmitted in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, without prior written permission of the publisher. Address permissions requests to: Elsevier Science Rights & Permissions Department, at the mail, fax and e-mail addresses noted above. Notice No responsibility is assumed by the Publisher for any injury and/or damage to persons or property as a matter of products liability, negligence or otherwise, or from any use or operation of any methods, products, instructions or ideas contained in the material herein. Because of rapid advances in the medical sciences, in particular, independent verification of diagnoses and drug dosages should be made. Although all advertising material is expected to conform to ethical (medical) standards, inclusion in this publication does not constitute a guarantee or endorsement of the quality or value of such product or of the claims made of it by its manufacturer.
02207 Printed by Mayfield Press, Oxon, UK.